Dublin, Oct. 04, 2024 (GLOBE NEWSWIRE) -- The "Chronic Urticaria: Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.
This report provides a data-driven overview of the current and future competitive landscape in chronic urticaria therapeutics.
In 2024, more than 60 million diagnosed prevalent cases of CU are anticipated in the 16 countries covered in the analyst's epidemiology forecast for CU.
The key players in the current CSU market include Regeneron/Sanofi with Dupixent (dupilumab) and Genentech/Novartis with Xolair (omalizumab).
There are 42 molecules in the pipeline for CU. The Phase III pipeline consists of three drugs, followed by 17 drugs in Phase II.
Over the past 10 years, the US has hosted the highest number of trial sites for CU, at 223 trial sites, followed by China with 186 trial sites.
During the past decade, in Asia-Pacific, North America, and Europe, acquisition deals were more prevalent.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Chronic urticaria market.
- Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Chronic urticaria market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.
Key Topics Covered
1 Table of Contents
1 Preface
1.1 Contents
1.2 Report Scope
1.3 List of Tables and Figures
1.4 Abbreviations
2 Key Findings
3 Disease Landscape
3.1 Disease Overview
3.2 Epidemiology Overview
3.3 Treatment Overview
4 Marketed Drugs Assessment
4.1 Leading Marketed Drugs
4.2 Overview by Mechanism of Action
4.3 Overview by Molecule Type
4.4 Product Profiles and Sales Forecast
5 Pricing and Reimbursement Assessment
5.1 Annual Cost of Therapy
5.2 Time to Pricing and Reimbursement
6 Pipeline Drugs Assessment
6.1 Mid-to-late-stage Pipeline Drugs
6.2 Overview by Development Stage
6.3 Overview by Mechanism of Action
6.4 Overview by Molecule Type
6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
6.6 Therapy Area and Indication-specific PTSR and LoA
7 Clinical Trials Assessment
7.1 Historical Overview
7.2 Overview by Phase
7.3 Overview by Status
7.4 Overview by Phase for Ongoing and Planned Trials
7.5 Trials with Virtual Components
7.6 Overview of Trials by Geography
7.7 Single-Country and Multinational Trials by Region
7.8 Top 20 Sponsors with Breakdown by Phase
7.9 Top 20 Sponsors with Breakdown by Status
7.10 Overview by Endpoint Status
7.11 Overview by Race and Ethnicity
7.12 Enrollment Data
7.13 Top 20 countries for Trial Sites
7.14 Top 20 Sites Globally
7.15 Feasibility Analysis - Geographic Overview
7.16 Feasibility Analysis - Benchmark Models
8 Deals Landscape
8.1 Mergers, Acquisitions, and Strategic Alliances by Region
8.2 Recent Mergers, Acquisitions, and Strategic Alliances
9 Commercial Assessment
9.1 Key Market Players
10 Future Market Catalysts
11 Appendix
11.1 Methodology
11.2 Methodology - Sales Forecast
11.3 Methodology - Pricing and Reimbursement
11.4 Methodology - PTSR and LoA Analysis
For more information about this report visit https://www.researchandmarkets.com/r/9ppuhe
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
